USA - NASDAQ:CELZ - US22529Y4089 - Common Stock
The current stock price of CELZ is 3.17 USD. In the past month the price decreased by -2.01%. In the past year, price decreased by -21.14%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
CREATIVE MEDICAL TECHNOLOGY
211 E. Osborn Rd.
Phoenix ARIZONA US
Employees: 4
Phone: 14803992822
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
The current stock price of CELZ is 3.17 USD. The price decreased by -3.06% in the last trading session.
CELZ does not pay a dividend.
CELZ has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
CREATIVE MEDICAL TECHNOLOGY (CELZ) operates in the Health Care sector and the Biotechnology industry.
CREATIVE MEDICAL TECHNOLOGY (CELZ) currently has 4 employees.
CREATIVE MEDICAL TECHNOLOGY (CELZ) has a market capitalization of 8.18M USD. This makes CELZ a Nano Cap stock.
ChartMill assigns a technical rating of 3 / 10 to CELZ. When comparing the yearly performance of all stocks, CELZ is a bad performer in the overall market: 76.63% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to CELZ. No worries on liquidiy or solvency for CELZ as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months CELZ reported a non-GAAP Earnings per Share(EPS) of -3.18. The EPS increased by 21.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.15% | ||
| ROE | -84.45% | ||
| Debt/Equity | 0 |
7 analysts have analysed CELZ and the average price target is 20.4 USD. This implies a price increase of 543.53% is expected in the next year compared to the current price of 3.17.
For the next year, analysts expect an EPS growth of 17.52% and a revenue growth -100% for CELZ